oa SA Pharmaceutical Journal - Efient® (prasugrel) : a new antiplatelet agent : new product focus - drug info
Efient®, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of atherothrombotic events in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention, as follows:
- Patients with unstable angina or non-ST segment elevation myocardial infarction, who are managed with percutaneous coronary intervention.
- Patients with ST-segment elevation myocardial infarction, who are managed with primary, or delayed, percutaneous coronary intervention.
Article metrics loading...